Yes, a PSEN2 genetic test can change dementia care decisions as symptoms progress. PSEN2 is a gene where certain harmful variants cause early-onset Alzheimer disease that runs in families. Symptoms most often start between ages 40 and 75. The American College of Medical Genetics and the National Society of Genetic Counselors report near-complete lifetime risk for carriers in their joint early-onset guidelines.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who should consider this test?
- What changes after a positive result?
- What care stays the same as symptoms progress?
- What steps and safeguards come with testing?
Who should consider this test?
The test fits a narrow group. It confirms diagnosis in a person with early-onset symptoms and offers risk testing to close blood relatives.
Clinical panels test APP, PSEN1, and PSEN2 together for this purpose. A reader can check fit with this list: The same ARUP Consult guidance says the panel finds a cause in about 60-80 percent of familial early-onset cases, with PSEN2 making up about 5 percent, and advises against ordering it when symptoms began after 65 in their early-onset panel guidance. Routine gene testing does not diagnose or predict most Alzheimer cases.
- symptoms began before age 65
- several relatives had early dementia
- a neurologist recommends the panel
What changes after a positive result?
A positive result confirms familial disease rather than sporadic Alzheimer. That answer shifts family planning. First-degree relatives face high risk and can seek cascade counseling, testing, and reproductive planning.
It can also open research options. Carriers may qualify for prevention trials for dominantly inherited Alzheimer disease, according to the UCSD listing for the DIAN-TU platform trial in its trial eligibility record. Families can ask the care team for referral information as needs increase.
What care stays the same as symptoms progress?
Drug treatment remains symptom management. No cure stops PSEN2-related decline. Families should plan for more supervision over time.
Daily support needs often grow step by step. Help with meals, safety, and personal care increases. Total care is often required in advanced stages.
What steps and safeguards come with testing?
Testing involves counseling before and after the blood draw. Pre-test counseling covers consent, family effects, and insurance effects. Post-test counseling explains results for the patient and relatives.
BlueCross BlueShield requires this counseling because results affect relatives' risk, insurance choices, and access to trials and early-stage amyloid-targeted drugs in its Alzheimer genetic testing policy. Those drugs also need separate amyloid confirmation. Ask a neurologist for a genetics referral before ordering the panel.
